Perspective Therapeutics (CATX) Operating Income (2010 - 2026)

Perspective Therapeutics has disclosed Operating Income across 17 years of filings, most recently posting -$29.3 million for Q2 2026.

• In Q2 2026, Operating Income fell 21.71% year-over-year to -$29.3 million; the TTM figure through Jun 2026 stood at -$103.4 million (up 5.55% YoY), while the FY2025 annual figure was -$113.6 million, down 24.95% from the prior year.
• Operating Income came in at -$29.3 million for Q2 2026 at Perspective Therapeutics, down from -$28.3 million in the prior quarter.
• In the past five years, Operating Income ranged from a high of -$1.4 million in Q1 2022 to a low of -$45.0 million in Q4 2024.
• Average Operating Income over 5 years is -$15.8 million, with a median of -$12.3 million recorded in 2023.
• Year-over-year, Operating Income slumped 609.38% in 2023 and decreased 21.71% in 2026.
• Over 5 years, Operating Income stood at -$5.6 million in 2022, then slumped by 107.72% to -$11.7 million in 2023, then slumped by 285.27% to -$45.0 million in 2024, then jumped by 46.56% to -$24.0 million in 2025, then dropped by 21.71% to -$29.3 million in 2026.
• Per Business Quant data, the three most recent Operating Income figures were -$29.3 million in Q2 2026, -$28.3 million in Q1 2026, and -$24.0 million in Q2 2025.